Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.

ESMO 2017 in-depth: RANGE trial

This year the ESMO congress took place in Madrid from 8 - 12 September. Daniel Petrylak, Professor of Medicine and Urology at Yale School of Medicine, explains the design and results of the RANGE trial. This phase III randomised trial evaluated the efficacy of ramucirumab in combination with docetaxel in patients with advanced urothelial cancer who failed prior platinum-based therapy.

  • Sponsors

    This program is editorially independent and is financially supported by: